Amikacin

Therapeutic indications

Amikacin is indicated for:

Bacterial infectious disease

Population group: both men and women, only adolescents (12 years - 18 years old) , adults (18 years old or older)

Amikacin is an aminoglycoside antibiotic which is active against a broad spectrum of Gram-negative organisms, including Pseudomonas spp, Escherichia coli, indole-positive and indole-negative Proteus spp. Klebsiella-Enterobacter-Serratia spp, Salmonella, Shigella, Minea-Herellae, Citrobacter freundii and Providencia spp.

Many strains of these gram-negative organisms resistant to gentamicin and tobramycin may show sensitivity to amikacin in vitro. The principal Gram-positive organism sensitive to amikacin is Staphylococcus aureus, including methicillin-resistant strains. Amikacin has some activity against other Gram-positive organisms including certain strains of Streptococcus pyogenes, Enterococci and Diplococcus pneumoniae.

Amikin is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria. It may also be indicated for the treatment of known or suspected staphylococcal disease.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Intravenous - 15 mg/kg in 2 divided doses daily

Treatment 2: Intramuscular - 15 mg/kg in 2 divided doses daily

Bacterial infectious disease

Population group: both men and women, only infants (40 days - 1 year old) , children (1 year - 12 years old)

Amikacin is an aminoglycoside antibiotic which is active against a broad spectrum of Gram-negative organisms, including Pseudomonas spp, Escherichia coli, indole-positive and indole-negative Proteus spp. Klebsiella-Enterobacter-Serratia spp, Salmonella, Shigella, Minea-Herellae, Citrobacter freundii and Providencia spp.

Many strains of these gram-negative organisms resistant to gentamicin and tobramycin may show sensitivity to amikacin in vitro. The principal Gram-positive organism sensitive to amikacin is Staphylococcus aureus, including methicillin-resistant strains. Amikacin has some activity against other Gram-positive organisms including certain strains of Streptococcus pyogenes, Enterococci and Diplococcus pneumoniae.

Amikin is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria. It may also be indicated for the treatment of known or suspected staphylococcal disease.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Intravenous - 15-20 mg/kg in 2 divided doses daily

Treatment 2: Intramuscular - 15-20 mg/kg in 2 divided doses daily

Bacterial infectious disease

Population group: both men and women, only newborns (0 - 40 days old)

Amikacin is an aminoglycoside antibiotic which is active against a broad spectrum of Gram-negative organisms, including Pseudomonas spp, Escherichia coli, indole-positive and indole-negative Proteus spp. Klebsiella-Enterobacter-Serratia spp, Salmonella, Shigella, Minea-Herellae, Citrobacter freundii and Providencia spp.

Many strains of these gram-negative organisms resistant to gentamicin and tobramycin may show sensitivity to amikacin in vitro. The principal Gram-positive organism sensitive to amikacin is Staphylococcus aureus, including methicillin-resistant strains. Amikacin has some activity against other Gram-positive organisms including certain strains of Streptococcus pyogenes, Enterococci and Diplococcus pneumoniae.

Amikin is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria. It may also be indicated for the treatment of known or suspected staphylococcal disease.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Intravenous - 15 mg/kg in 2 divided doses daily

Treatment 2: Intramuscular - 15 mg/kg in 2 divided doses daily

Peritonitis

Population group: both men and women, only minors (0 - 18 years old) , adults (18 years old or older)

Peritonitis
and additionally
Amikacin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Intraperitoneal - 500 mg once

Contraindications

Amikacin is contraindicated in the following cases:

Pregnancy

Pregnancy

Anaesthetics, muscle-relaxing drugs

at least one of
Anesthetics

Diethyl ether

Halothane

Tubocurarine

SUCCINYLCHOLINE

DECAMETHONIUM

Atracurium besilate

Rocuronium

Vecuronium

Neurotoxic, ototoxic or nephrotoxic agents

at least one of
Bacitracin

Cis-Diaminedichloroplatinum

Carboplatin

Oxaliplatin

Amphotericin B

Ciclosporin

Tacrolimus

CEPHALORIDINE

Paromomycin

VIOMYCIN

Polymyxin B

Colistin

Vancomycin

Myasthenia gravis

Myasthenia gravis

Hypersensitivity to aminoglycosides

Aminoglycoside allergy